Subcellular localization, modification and protein complex formation of the cdk-inhibitor p16 in Rb-functional and Rb-inactivated tumor cells

International Journal of Cancer

Volumn 118, Issue 5, 2006, Pages 1120-1125

  Nilsson, Kristina ^a   Landberg, Göran ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

p16; Retinoblastoma gene product; Two dimensional gel electrophoresis

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; PROTEIN P16INK4A; RETINOBLASTOMA PROTEIN;

ARTICLE; BASAL CELL CARCINOMA; BREAST CANCER; CELL NUCLEUS; CELLULAR DISTRIBUTION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOPLASM; GEL FILTRATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SQUAMOUS CELL CARCINOMA; TUMOR CELL; TUMOR SUPPRESSOR GENE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

CELL LINE, TUMOR; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYTOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; NEOPLASMS; PROTEIN BINDING; PROTEIN TRANSPORT; RETINOBLASTOMA PROTEIN;

EID: 31844446633     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21466     Document Type: Article

References (34)

1. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
2. Reed SI. Control of the G1/S transition. Cancer Surv 1997;29:7-23.
3. Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001;264:42-55.
4. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
5. Serrano M. The tumor suppressor protein p16INK4a. Exp Cell Res 1997;237:7-13.
6. Hirabayashi H, Fujii Y, Sakaguchi M, Tanaka H, Yoon HE, Komoto Y, Inoue M, Miyoshi S, Matsuda H. p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. Int J Cancer 1997;73:639-44.
7. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998;1378:F115-F177.
8. Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 1996;16:859-67.
9. Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 1998;395:237-4.
10. Gump J, Stokoe D, McCormick F. Phosphorylation of p16INK4A correlates with Cdk4 association. J Biol Chem 2003;278:6619-22.
11. Thullberg M, Bartkova J, Khan S, Hansen K, Ronnstrand L, Lukas J, Strauss M, Bartek J. Distinct versus redundant properties among members of the INK4 family of cyclin-dependent kinase inhibitors. FEBS Lett 2000;470:161-6.
12. Weebadda WK, Jackson TJ, Lin AW. Expression of p16INK4A variants in senescent human fibroblasts independent of protein phosphorylation. J Cell Biochem 2005;94:1135-47.
13. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995;375:503-6.
14. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996;56: 5475-83.
15. Geradts J, Hruban RH, Schutte M, Kern SE, Maynard R. Immunohistochemical p16INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/MTS1 gene. A comparison of four commercial antibodies. Appl Immunohistochem Mol Morphol 2000;8:71-9.
16. Walker GJ, Gabrielli BG, Castellano M, Hayward NK. Functional reassessment of P16 variants using a transfection-based assay. Int J Cancer 1999;82:305-12.
17. Rizos H, Darmanian AP, Holland EA, Mann GJ, Kefford RF. Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF. J Biol Chem 2001;276:41424-34.
18. Hashemi J, Lindstrom MS, Asker C, Platz A, Hansson J, Wiman KG. A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF. Cancer Lett 2002;180: 211-21.
19. Ghiorzo P, Villaggio B, Sementa AR, Hansson J, Platz A, Nicolo G, Spina B, Canepa M, Palmer JM, Hayward NK, Bianchi-Scarra G. Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients. Hum Pathol 2004; 35:25-33.
20. Wang NP, To H, Lee WH, Lee EY. Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells. Oncogene 1993;8: 279-88.
21. Kim MS, Li SL, Bertolami CN, Cherrick HM, Park NH. State of p53, Rb and DCC tumor suppressor genes in human oral cancer cell lines. Anticancer Res 1993;13:1405-13.
22. Craig C, Kim M, Ohri E, Wersto R, Katayose D, Li Z, Choi YH, Mudahar B, Srivastava S, Seth P, Cowan K. Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. Oncogene 1998;16:265-72.
23. Lee JK, Kim MJ, Hong SP, Hong SD. Inactivation patterns of p16/INK4A in oral squamous cell carcinomas. Exp Mol Med 2004;36: 165-71.
24. Svensson S, Nilsson K, Ringberg A, Landberg G. Invade or proliferate? Two contrasting events in malignant behavior governed by p16(INK4a) and an intact Rb pathway illustrated by a model system of basal cell carcinoma. Cancer Res 2003;63:1737-42.
25. Ragione FD, Russo GL, Oliva A, Mercurio C, Mastropietro S, Pietra VD, Zappia V. Biochemical characterization of p16INK4- and p18-containing complexes in human cell lines. J Biol Chem 1996;271: 15942-49.
26. Emig R, Magener A, Ehemann V, Meyer A, Stilgenbauer F, Volkmann M, Wallwiener D, Sinn HP. Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation. Br J Cancer 1998;78:1661-8.
27. Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 2000;6:1845-53.
28. Milde-Langosch K, Bamberger AM, Rieck G, Kelp B, Loning T. Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat 2001;67:61-70.
29. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, Mizutani S. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. Embo J 1999;18:1223-34.
30. Nikolaev AY, Li M, Puskas N, Qin J, Gu W. Parc: a cytoplasmic anchor for p53. Cell 2003;112:29-40.
31. Blain SW, Massague J. Breast cancer banishes p27 from nucleus. Nat Med 2002;8:1076-8.
32. Nilsson K, Svensson S, Landberg G. Retinoblastoma protein function and p16(INK4a) expression in actinic keratosis, squamous cell carcinoma in situ and invasive squamous cell carcinoma of the skin and links between p16(INK4a) expression and infiltrative behavior. Mod Pathol 2004;17:1464-74.
33. Fahraeus R, Lane DP. The p16(INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts. Embo J 1999;18:2106-18.
34. Kwon TK, Buchholz MA, Gabrielson EW, Nordin AA. A novel cytoplasmic substrate for cdk4 and cdk6 in normal and malignant epithelial derived cells. Oncogene 1995;11:2077-83.